Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Rusalatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R known ✓ | P32245 | 2/20 | 0.57 |
| ▸ | MC1R known ✓ | Q01726 | 2/20 | 0.57 |
| ▸ | RAMP3 known ✓ | O60896 | 1/20 | 0.55 |
| ▸ | CALCR known ✓ | P30988 | 1/20 | 0.55 |
| ▸ | TFPI | P10646 | 5/20 | 0.62 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.59 |
| ▸ | MC5R | P33032 | 2/20 | 0.57 |
| ▸ | MC3R | P41968 | 2/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 5/20 | 0.56 |
| ▸ | NPY4R | P50391 | 5/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.56 |
| ▸ | NPY1R | P25929 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rusalatide SCHEMBL29392126 | 0.99 | EPHA2 (0.62) | TFPIEPHA2CXCR4MC4RMC5R | |
| SCHEMBL30415710 | 0.97 | EPHA2 (0.65) | TFPIEPHA2MC4RMC5RMC3R | |
| SCHEMBL30415381 | 0.97 | EPHA2 (0.65) | TFPIEPHA2MC4RMC5RMC3R | |
| SCHEMBL30415150 | 0.96 | EPHA2 (0.62) | TFPIEPHA2CXCR4NPY2RNPY4R | |
| SCHEMBL31473050 | 0.95 | CXCR4 (0.61) | TFPIEPHA2CXCR4NPY2RNPY4R | |
| SCHEMBL29390108 | 0.94 | EPHA2 (0.62) | TFPIEPHA2CXCR4MC4RMC5R | |
| SCHEMBL30415361 | 0.94 | EPHA2 (0.65) | TFPIEPHA2CXCR4NPY2RNPY4R | |
| SCHEMBL30186412 | 0.92 | EPHA2 (0.65) | TFPIEPHA2MC4RMC5RMC3R | |
| SCHEMBL29392765 | 0.90 | EPHA2 (0.57) | TFPIEPHA2CXCR4NPY2RNPY4R | |
| SCHEMBL29389698 | 0.89 | EPHA2 (0.56) | TFPIEPHA2CXCR4NPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600949-B2 | Modified macrophages, compositions and uses thereof | Duogenic StemCells Corporation (TW) | 2026-04-14 | — | — | US | claimed |
| US-20250312463-A1 | AUGMENTED PEPTIDE COMPOSITIONS AND METHODS | Neo7Bioscience, Inc. (US) | 2025-10-09 | — | — | US | claimed |
| US-12280041-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2025-04-22 | — | — | US | claimed |
| EP-4474384-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | Novartis AG (CH) | 2024-12-11 | — | — | EP | claimed |
| EP-3143026-B1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2024-07-10 | — | — | EP | claimed |
| US-20230142987-A1 | MODIFIED MACROPHAGES, COMPOSITIONS AND USES THEREOF | Duogenic StemCells Corporation (TW) | 2023-05-11 | — | — | US | claimed |
| US-20230112980-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2023-04-13 | — | — | US | claimed |
| EP-4139441-A1 | MODIFIED MACROPHAGES, COMPOSITIONS AND USES THEREOF | Duogenic Stemcells Corporation (TW) | 2023-03-01 | — | — | EP | claimed |
| CN-115667502-A | Modified macrophages, compositions thereof and uses thereof | 通用干细胞股份有限公司 | 2023-01-31 | — | — | CN | claimed |
| US-11510912-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2022-11-29 | — | — | US | claimed |
| CN-114763347-A | Compound for inducing mesenchymal stem cells to differentiate towards cartilage and application thereof | 华东师范大学 | 2022-07-19 | — | — | CN | claimed |
| CN-114763346-A | Compound for inducing chondrogenesis and application thereof | 华东师范大学 | 2022-07-19 | — | — | CN | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12600949-B2 | Modified macrophages, compositions and uses thereof | Duogenic StemCells Corporation (TW) | 2026-04-14 | — | — | US | disclosed |
| US-12569594-B2 | Decellularized tendon matrix methods and uses thereof | THE STEADMAN CLINIC AND STEADMAN PHILIPPON RESEARCH INSTITUTE (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260062709-A1 | METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN | LONZA AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20220033412-A1 | 6-HYDROXY-8-OXATRICYCLO[3.2.1.02,4]OCTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | NOVARTIS AG (CH) | 2022-02-03 | — | — | US | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033412-A1 | 6-HYDROXY-8-OXATRICYCLO[3.2.1.02,4]OCTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | COL2A1, COL1A1, HCAR1 | MC4R 344/4885MC1R 670/4885RAMP3 883/4885 |
| US-20230112980-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, COL2A1, FGFR3 | MC4R 550/4885MC1R 1503/4885RAMP3 4029/4885 |
| US-12600949-B2 | Modified macrophages, compositions and uses thereof | CD14, CD68, CD209 | MC4R 880/4885MC1R 584/4885RAMP3 317/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | MC4R 222/4885MC1R 368/4885RAMP3 1036/4885 |
| US-20260062709-A1 | METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN | MRPL21, SET, RPS27A | MC4R 4184/4885MC1R 4079/4885RAMP3 1526/4885 |
| US-11510912-B2 | Compounds and compositions for inducing chondrogenesis | FGF1, COL2A1, FGFR3 | MC4R 550/4885MC1R 1503/4885RAMP3 4029/4885 |
| US-12569594-B2 | Decellularized tendon matrix methods and uses thereof | DNASE1, MMP1, MMP9 | MC4R 4265/4885MC1R 3258/4885RAMP3 1130/4885 |
| US-12280041-B2 | Compounds and compositions for inducing chondrogenesis | FGF1, COL2A1, FGFR3 | MC4R 550/4885MC1R 1503/4885RAMP3 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.